FDA 突破性器械计划：创新医疗器械出海美国的黄金加速通道！ - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > FDA Breakthrough Devices Program: The Golden Fast Track for Innovative Medical Devices Entering the U.S. Market

FDA Breakthrough Devices Program: The Golden Fast Track for Innovative Medical Devices Entering the U.S. Market

Time：2026-06-18 14:47:04

As the global benchmark for medical device regulation, the U.S. FDA’s Breakthrough Devices Program delivers an expedited review mechanism that serves as a core shortcut for domestic and overseas innovative devices to access the U.S. market. Drawing on the FDA’s latest official rules and authoritative data up to March 2026, this article provides a comprehensive breakdown of this pivotal policy, delivering practical references for medical device manufacturers expanding overseas.

原

文

链

接

https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

一、Program Background

The Breakthrough Devices Program is a voluntary regulatory acceleration initiative targeting medical devices and device-led combination products. Its core mission is to speed up the commercialization of innovative devices for treating or diagnosing life-threatening conditions and illnesses causing irreversible bodily impairment, enabling patients and medical institutions to access cutting-edge medical technologies sooner.

This program integrates and replaces the FDA’s former Expedited Access Pathway (EAP) and medical device priority review scheme. All devices previously designated under EAP are now governed by the Breakthrough Devices Program uniformly.A critical clarification: Breakthrough Device designation does not equate to market approval. This status only grants eligibility for an expedited review track. All products must still undergo full FDA evaluation of safety and efficacy to obtain marketing clearance; core regulatory standards will not be relaxed, striking a balance between industrial innovation and public health protection.

二、Eligibility Criteria

Not all devices qualify for designation. Regardless of whether manufacturers pursue Premarket Approval (PMA), 510(k) Premarket Notification, or De Novo classification, two mandatory criteria must be satisfied simultaneously:

Criterion 1：The device delivers superior therapeutic or diagnostic solutions for life-threatening illnesses or conditions that trigger irreversible physical deterioration.

Criterion 2 (at least one subcondition must be met on top of Criterion 1)：

Breakthrough Technology: Major revolutionary upgrades to technical routes and working principles that disrupt conventional diagnosis and treatment modalities;

No Approved Alternatives: No FDA-cleared or approved equivalent devices are commercially available in the U.S.;

Substantial Advantages Over Existing Products: Outperforms marketed alternatives comprehensively in therapeutic efficacy, safety, ease of operation, or clinical cost efficiency;

Strong Patient Benefit: Addresses unmet critical clinical needs, with early commercialization capable of materially improving patient quality of life and cure rates.

Common application categories include cardiovascular interventional devices, neurological diagnostic & therapeutic equipment, AI-assisted diagnostic systems, rare disease-specific instruments, and implantable life-support devices.

三、Core Program Benefits

Sponsors who secure Breakthrough Device designation receive exclusive end-to-end FDA support, the program’s most attractive advantage:

End-to-End Priority Review：All subsequent submissions including Q-Submission inquiries, Investigational Device Exemption (IDE) applications, and formal marketing applications are prioritized, drastically shortening overall review timelines.

Dedicated Expert Engagement Throughout Development：The FDA assigns specialized technical experts to each sponsor for continuous communication via dedicated workshops, data development plan consultations, and clinical protocol alignment. Official real-time feedback helps manufacturers avoid developmental and filing pitfalls, reducing supplementary data requests and protocol revisions while cutting R&D trial-and-error costs.

Flexible Communication Framework：Sponsors may submit communication requests at any stage from early R&D through marketing submission. The FDA provides clear, timely guidance addressing technical hurdles and dossier requirements.

Cross-Referral to Complementary Accelerated Pathways：If a device fails to meet Breakthrough Program eligibility, the FDA will refer sponsors to alternative expedited tracks such as the Safer Technologies Program (STeP) to maximize speed to market.

四、Step-by-Step Operational Guidance

（一）Application Timing

Manufacturers may submit designation requests at any stage prior to filing a formal marketing application. Submission mid-R&D is recommended to secure expedited track advantages early.

（二）Submission Method & Required Dossiers

File a dedicated Breakthrough Device Designation Q-Submission via the CDRH Customer Collaboration Portal. This standalone submission must contain only the designation request and no additional unrelated inquiries.

Complete application materials include:

General device overview

Intended use and indications

Regulatory history

Supporting arguments proving compliance with Breakthrough designation standards

Planned marketing submission pathway (PMA / 510(k) / De Novo)

（三）FDA Official Review Timelines

Within 30 calendar days of receipt: The FDA notifies sponsors whether supplementary supporting evidence is required;

Within 60 calendar days of receipt: The FDA issues a formal designation decision (approval or denial) with an official mailed letter.

Critical Reminder: Failure to promptly respond to FDA requests for supplementary materials will result in automatic rejection of the application. Timely communication is essential.

五、Latest Industry Statistics

Official FDA data illustrates the program’s widespread adoption and tangible market outcomes:

（一） Total Designation Count

Cumulative Breakthrough Device designations issued by CDRH (Center for Devices and Radiological Health) and CBER (Center for Biologics Evaluation and Research) stand at 1,284:

CDRH: 1,264 device designations (dominant share)

CBER: 20 combination/biomedical product designations

（二）Breakdown by Clinical Segment (reflecting FDA & global innovation priorities)

Cardiovascular: 260 designations (high demand for interventional and implantable devices)

Neurology: 200 designations

Orthopedics: 176 designations

Gastroenterology & Urology: 119 designations

General & Plastic Surgery: 78 designations

（三）Commercialization Conversion Results

198 designated devices have obtained U.S. marketing authorization to date:

CDRH medical devices: 193 cleared/approved products

CBER-regulated products: 5 authorized products

Multiple flagship devices received consecutive approvals between late 2025 and March 2026, covering heart valve systems, orthopedic screws, AI diagnostic algorithms, medical imaging platforms, spinal repair implants, etc. Approvals include products from global giants such as Medtronic and Abbott, alongside innovations from emerging global biotech manufacturers.

六、Conclusion

The FDA Breakthrough Devices Program represents a regulatory innovation framework that incentivizes clinical unmet need-driven innovation, optimizes review efficiency, and upholds rigorous safety benchmarks. For medical device manufacturers focused on severe and rare disease treatment, this track acts as an accelerator to penetrate the high-value U.S. healthcare market. It shortens time to market and reduces compliance overhead, while Breakthrough designation itself serves as authoritative global validation of product competitiveness.

Previous：Decipher Singapore’s MDPR Certificates: Risk Classification, Certificate Rules & Overseas Market Entry Logic Next：Russia Postpones New Medical Device Registration Rules Again – Extended Transition Period for Foreign Manufacturers’ Authorized Representatives

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.